Drug-resistant e. coli bacteremia transmitted by fecal microbiota transplant

New England Journal of Medicine

Volumn 381, Issue 21, 2019, Pages 2043-2050

  DeFilipp, Zachariah ^a   Bloom, Patricia P ^b   Soto, Mariam Torres ^b   Mansour, Michael K ^b   Sater, Mohamad R A ^b   Huntley, Miriam H ^b   Turbett, Sarah ^b   Chung, Raymond T ^b   Chen, Yi Bin ^a   Hohmann, Elizabeth L ^b  

^a Division of Gastroenterology

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE;

AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CASE REPORT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; DONOR; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FECAL MICROBIOTA TRANSPLANTATION; GRAM NEGATIVE SEPSIS; HEPATIC ENCEPHALOPATHY; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; SCREENING; ADVERSE EVENT; BACTEREMIA; COMPLICATION; DRUG EFFECT; DYSBIOSIS; ESCHERICHIA COLI; FATALITY; FECES; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MYELODYSPLASTIC SYNDROME;

AGED; BACTEREMIA; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; DYSBIOSIS; ESCHERICHIA COLI; FATAL OUTCOME; FECAL MICROBIOTA TRANSPLANTATION; FECES; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 85075711452     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1910437     Document Type: Article

References (27)

1. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569-80.
2. Mullish BH, Quraishi MN, Segal JP, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2018; 67: 1920-41.
3. Gupta A, Cifu AS, Khanna S. Diagnosis and treatment of Clostridium difficile infection. JAMA 2018; 320: 1031-2.
4. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: Systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-8.
5. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-15.
6. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772-8.
7. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: 987-94.
8. DeFilipp Z, Hohmann E, Jenq RR, Chen YB. Fecal microbiota transplantation: Restoring the injured microbiome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2019; 25(1): E17-e22.
9. DeFilipp Z, Peled JU, Li S, et al. Thirdparty fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2018; 2: 745-53.
10. Krajicek E, Fischer M, Allegretti JR, Kelly CR. Nuts and bolts of fecal microbiota transplantation. Clin Gastroenterol Hepatol 2019; 17: 345-52.
11. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1036-8.
12. Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018; 2018: 1394379.
13. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014; 8: 252-3.
14. Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PG. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25: 255-7.
15. Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal transplant. Clin Infect Dis 2014; 59: 319.
16. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 2015; 61: 136-7.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: CLSI supplement M100. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2019.
18. Grad YH, Lipsitch M, Feldgarden M, et al. Genomic epidemiology of the Escherichia coli O104:H4 outbreaks in Europe, 2011. Proc Natl Acad Sci USA 2012; 109: 3065-70.
19. Peacock SJ, Parkhill J, Brown NM. Changing the paradigm for hospital outbreak detection by leading with genomic surveillance of nosocomial pathogens. Microbiology 2018; 164: 1213-9.
20. Schürch AC, Arredondo-Alonso S, Willems RJL, Goering RV. Whole genome sequencing options for bacterial strain typing and epidemiologic analysis based on single nucleotide polymorphism versus gene-by-gene-based approaches. Clin Microbiol Infect 2018; 24: 350-4.
21. Millan B, Park H, Hotte N, et al. Fecal microbial transplants reduce antibioticresistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 2016; 62: 1479-86.
22. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209.
23. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. Silver Spring, MD: Food and Drug Administration, June 13, 2019 (http://www .fda .gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse).
24. Gordon NC, Pichon B, Golubchik T, et al. Whole-genome sequencing reveals the contribution of long-term carriers in Staphylococcus aureus outbreak investigation. J Clin Microbiol 2017; 55: 2188-97.
25. Lavigne JP, Blanc-Potard AB, Bourg G, et al. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases. Clin Microbiol Infect 2006; 12: 1199-206.
26. Deschamps C, Clermont O, Hipeaux MC, Arlet G, Denamur E, Branger C. Multiple acquisitions of CTX-M plasmids in the rare D2 genotype of Escherichia coli provide evidence for convergent evolution. Microbiology 2009; 155: 1656-68.
27. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: A successful or deleterious association in the bacterial world Clin Microbiol Rev 2013; 26: 185-230.